Arc of Support, Abraxis Oncology Resource Center
Monday–Friday, 8:00 am–8:00 pm, EST
800.564.0216

The Arc of Support is a comprehensive program that provides a broad range of services for healthcare professionals caring for patients undergoing treatment with Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound).

Metastron®Reimbursement Hotline
Monday–Friday, 9 am–5 pm, EST
800.767.6664

Amersham has established a toll-free Reimbursement Hotline that customers may use to speak with a reimbursement specialist. Specific coding and payment issues are individualized by state to assist the customer with appropriate reimbursement. Updated publications related to specific questions can be provided via fax or mail to reinforce information provided verbally.

Amersham Reimbursement Services
Monday–Friday, 8:30 am–5:30 pm, EST
800.767.6664

Callers may obtain coverage, coding, and reimbursement information.

Amgen Reimbursement Connection™
Monday–Friday, 9 am–8 pm, EST
800.272.9376

The Reimbursement Connection ™ is a full-service hotline for reimbursement and patient assistance for those who are interested in Neupogen® (filgrastim), Aranesp ™ (darbepoetin alfa), and Neulasta ™ (pegfilgrastim).

The Reimbursement Connection is a free resource providing information on reimbursement policies, billing and coding, and claims appeals. Reimbursement Connection staff can conduct insurance verifications upon request. Staff can provide information about Amgen’s SAFETY NET® Program, which replaces Neupogen, Aranesp, and Neulasta to sponsors of medically needy patients who are underinsured or uninsured and meet specific program eligibility criteria. Providers can pre-qualify eligible patients for the SAFETY NET Program over the phone with appropriate patient consent. The Reimbursement Connection also assists patients by reviewing their insurance options and referring appropriate patients to alternative funding resources, such as state- or county-based funding when appropriate.

AstraZeneca Cancer Support Network (AZ CSN)
Monday–Friday, 9:00 am–8:00 pm ET
1.866.992.9276

The AstraZeneca Cancer Support Network a toll-free service staffed by specially trained nurses, pharmacists, and reimbursement specialists to provide up-to-date information and answers to questions about clinical trials for AstraZeneca oncology products, disease state information, reimbursement and access and payer coverage.

The AZ CSN supports the following products: Arimidex 1 mg (anastrozole tablets), Faslodex IM injection (fulvestrant), Zoladex 3.6 mg (goserelin acetate implant), Zoladex 10.8 mg, and Casodex 50 mg (bicalutamide tablets). Reimbursement specialists are available to assist callers with coverage and reimbursement issues relating to Medicare Parts A, B, D and Medicare Advantage as well as Medicaid, private third-party payers, and managed care organizations.

Alternative database searches are available to further assist patients in finding coverage from other resources if needed. Callers may obtain coding recommendations (HCPCS, CPT, ICD-9), assistance with denied or under-reimbursed claims, general coverage and reimbursement information.

On-line assistance is also now available at www.azcsn.net.

Nexavar®/REACH Helpline
Monday–Friday, 9 am–8 pm, EST
1.866 NEXAVAR (1.866.639.2827, Essential Support Is Within REACH, Resources for Expert Assistance and Care Helpline

The Resources for Expert Assistance and Care Helpline is available to answer questions about Nexavar treatment, reimbursement, and patient support. The REACH program, developed by Bayer and Onyx Pharmaceuticals, provides physicians and patients with clinical information about Nexavar and helps with insurance questions and claims, as well as assists with prescriptions and reimbursement inquiries. REACH is supported by a team of counselors dedicated to helping patients and physicians understand coverage and navigate the reimbursement system and Medicare Part D. REACH is also designed to support patients as they transition from the Nexavar expanded access treatment protocol.

CamCareTM Support Line
Campath® (alemtuzumab)
Fludara® (fludarabine phosphate)
Monday–Friday, 8 am–5 pm, EST
800.473.5832

The CamCare program supports providers, patients, and caregivers throughout treatment with Fludara (fludarabine phosphate) and Campath (alemtuzumab). Trained reimbursement consultants provide personalized assistance to help facilitate reimbursement and ensure patient access to therapy. Consultants are available by phone to answer reimbursement questions regarding coding, preparation of insurance claims and claim appeals. In addition to claims support, consultants can reach patient-specific insurance coverage, assist uninsured patients through a patient assistance program, and explore sources of alternate coverage for patients. The CamCare Support Line also provides patients and providers with access to a team of registered nurses who specialize in cancer care and treatment. This dedicated team of nurse consultants provides nurses and patients with around-the-clock clinical support for Campath therapy.

Leukine® Reimbursement Hotline
Monday–Friday, 9 am–8 pm, EST
800.321.4669

The Leukine® Reimbursement Hotline offers third-party billing information for Leukine® (sargramostim). Reimbursement specialists provide assistance to identify informational requirements of individual insurers, facilitate prior authorization requests, and assist in appeals of denied claims. The hotline provides one-on-one assistance with claims filing guidelines, including CPT-4 and HCPCS coding. A 24-hour dedicated fax machine is available at 800-944-3184. These services are available free of charge to health care professionals by request only.

Quadramet® Reimbursement Hotline
Monday–Friday, 9 am–5 pm, EST
800.473.5832

Quadramet® (Samarium-153 [EDTMP] lexidronam injection) is a radiopharmaceutical indicated for the treatment of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan. The Berlex Reimbursement Hotline for Quadramet is a free information resource available to anyone who may have questions about insurance coverage or reimbursement. The associates who staff the Reimbursement Hotline for Quadramet are highly trained service professionals who can provide assistance in patient-specific coverage and claims filing. In addition, if an insurer should deny or delay reimbursement, hotline associates can analyze the claim and recommend an appeal strategy.

Rituxan® Single Point of Contact (SPOC) Reimbursement
Reimbursement Support Line - Trained Specialists
Monday–Friday, 6:00 am–5:00 pm, ET
1.800.386.9997

Biogen Idec recognizes the importance of coverage, payment, and accurate coding, and is committed to providing assistance through a dedicated Reimbursement Support Line. The Reimbursement Support Line is staffed with trained specialists in payer relations, coding and payment issues unique to Rituxan. These specialists will help you understand the various coding options across sites of service, physician’s office and hospital outpatient, and help you complete correct claim forms for submission to insurance companies.

Destination Access
Monday–Friday, 7:00 am–7:00 pm, CST
800.861.0048

The service is designed to assist callers from the medical community with reimbursement issues surrounding all Bristol-Myers Squibb Oncology and Immunology products. The hotline is staffed by trained reimbursement specialists who will provide information on third-party coverage guidelines, claim requirements of individual third-party payers, limitations of specific policies, drug and procedures coding, and names and addresses of third-party payers. The hotline offers assistance in providing details on claim form submission, identifying reasons for claim rejection, providing guidelines and literature for claim appeals, facilitating prior authorization requests, and contacting insurers when appropriate in the process of claim submission. The hotline is designed for providers in the United States.

Patient Support Coordinator (PSC) Program
Monday–Friday, 8 am–7 pm, EST
Phone: 800.931.8691
Email: patientsupport@celgene.com
Web: www.celgenepsc.com

Patient Support Coordinator®
This program offers a dedicated central point of contact to assist providers and cancer patients navigate the challenges of reimbursement, provide information about co-pay assistance, and answer general questions about Celgene products and their distribution.

The Patient Support Coordinator assists cancer patients with:

• Reimbursement assistance, insurance claims, and appeals
• Medicare Part D prescription drug benefit issues
• Locating co-pay assistance programs and services
• Identifying pharmacies that are registered to dispense Celgene products
• Determining the status of a prescription
• Inquiries regarding Celgene’s patient assistance program
• Information regarding Celgene products and their restricted distribution programs (RevAssist® or S.T.E.P.S.®) or appropriate contacts for other questions.

Reimbursement Hotline and Patient Assistance Program
Monday–Friday, 8 am–8 pm, EST
Phone: 866.742.7646

This hotline provides reimbursement assistance for Vidaza® (azacitidine for injectable suspension) and Innohep® (tinzaparin sodium injection). Our team of reimbursement specialists can help address coverage, coding and payment issues as well as answer questions about Medicare, Medicaid, commercial insurers, and managed care. They also can provide information about the Patient Assistance Program, which was established to help patients who otherwise might not have access to our products.

Zevalin RESULTS
Reimbursement Support Line
Monday–Friday, 9 am–6 pm, ET
866.298.8433 Option 4

The Reimbursement Support Line is staffed with trained specialists in payer relations, coding and payment issues unique to the Zevalin (ibritumomab tiuxetan) regimen. These specialists will help you understand the various coding options across sites of service, physician’s office and hospital outpatient, and help you complete correct claim forms for submission to insurance companies. In addition, the specialists will help you navigate through the prior authorization process for the Zevalin regimen and verify insurance benefits specific to your patients’ plans. Zevalin, as part of the Zevalin therapeutic regimen, is indicated for the treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients with Rituxan (rituximab) refractory follicular NHL.

FENTORA Patient Assistance Program
Monday–Friday, 9 am–8 pm, EST
Hotline: 1.877.4FENTORA (1.877.433.6867)
Fax: 1.866.495.0657

Eligibility: Patients who do not have prescription drug coverage could be eligible for the FENTORA® Patient Assistance Program. The patient must not be eligible for public and private insurance reimbursement (including Medicare Part D), and must meet certain income restrictions and U.S. residency requirements.

Cephalon Oncology Reimbursement Expertise™ (CORE)
Monday–Friday, 9am–6pm, EST
1.866.261.7730
Web: www.cephalononcologycore.com

Cephalon Oncology's reimbursement support program, CORE or Cephalon Oncology Reimbursement Expertise™, supports Cephalon Oncology’s product TRISENOX® (arsenic trioxide). Assistance from CORE can be accessed by calling toll free at 1-866-261-7730 or by using the CORE website found at www.cephalononcologycore.com.

CORE services are provided to both healthcare professionals and patients. For oncology practices, CORE can provide benefit verifications, coding and claims support, letter of medical necessity templates, assistance in locating relevant medical literature, access to the Cephalon Oncology Patient Assistance Program and appeals support.

Chiron Reimbursement Service
Monday–Friday, 8 am-5 pm, PST
After hours, leave a message.
800.775.7533

The Chiron Reimbursement Service provides reimbursement support for Chiron BioPharmaceuticals' products: Proleukin® (aldesleukin for injection), a recombinant interleukin-2 (rIL-2), which is approved for metastatic renal cell carcinoma and metastatic melanoma, and DepoCyt (cytarabine liposome injection), encapsulated cytarabine approved for the intrathecal treatment of lymphomatous meningitis.

The Chiron Reimbursement Service reimbursement consultants help to minimize claims processing delays and provide information about coding, prior authorization procedures, patient coverage status, and reimbursement amounts and limitations. The reimbursement specialists also determine the status of and reasons for denied claims and assist with filing appeals for denied claims.

Cytogen Reimbursement Hotline
Monday–Friday, 8:30 am–4:30 pm, ET
866.369.9290

Reimbursement specialists are available to assist physicians and institutions with billing, coding, and reimbursement questions pertaining to public payers and private insurers. ProstaScint® is a monoclonal antibody-based diagnostic imaging agent for use in two clinical settings: 1) newly diagnosed patients with biopsy-proven prostate cancer thought to be clinically localized after standard diagnostic evaluation and who are at high risk for pelvic lymph node metastases and 2) post-prostatectomy patients with a rising prostate-specific antigen (PSA) and a negative or equivocal standard metastatic evaluation in whom there is a high clinical suspicion of occult metastatic disease.

CARE OM is a web-based education and support center for patients and caregivers seeking to learn more about oral mucositis (OM) and Caphosol®, an advanced electrolyte solution indicated in the U.S. as an adjunct to standard oral care in treating OM caused by radiation or high-dose chemotherapy. Caphosol, a prescription medical device, is also indicated for dryness of the mouth or throat (hyposalivation, xerostomia), regardless of the cause or whether the conditions are temporary or permanent. In addition to oral mucositis educational material and support information, visitors to CARE OM can also download an OM brochure or request a free brochure about OM by mail.

Lilly PatientOne
Monday–Friday, 9 am–7 pm EST
1.866.472.8663, option 1 (1.866.4PatOne, option 1)

Lilly PatientOne is the Lilly oncology program that addresses financial, access, and claim issues for patients who are candidates for Alimta (pemetrexed for injection) and/or Gemzar (gemcitabine HCL for injection).

Among the many services are: reliable, individualized treatment support and patient assistance, including insurance verification and claim submission assistance; information about payment methodologies and allowables and drug information and coding; and claim appeals, a full, start-to-finish commitment.

Genentech Reimbursement Hotline
Monday–Friday, 8 am–5 pm, PST
800.530.3083

Reimbursement specialists provide information, counseling, and hands-on assistance for problems with reimbursement for Genentech products: Activase® (alteplase, recombinant), Avastin™ (bevacizumab), Herceptin® (Trastuzamab), Nutropin® [somatropin (r DNA origin) for injection], Nutropin AQ® (somatrem for injection), Nutropin AQ Pen ™ Cartridge [somatropin (r DNA origin) injection], Rituxan ™ (Rituximab), Tarceva® (erlotinib). Information regarding Genentech Access to Care Foundation, established to provide medically indicated products to patients who are uninsured and have limited financial resources, is also provided.

Avastin Patient Assistance Program
Single Point of Contact (SPOC)
Monday–Friday, 6 am–5 pm PST
Phone: 888.249.4918
Fax: 888.249.4919

The Avastin Patient Assistance Program is designed to limit the overall annual cost of Avastin for eligible patients receiving treatment for FDA-approved indications. Participation in the program provides a voluntary opportunity for physicians and eligible patients who reach an annual charge of 10,000 mg to receive free Avastin from Genentech for the remainder of the 12-month period. The program is open to all patients receiving Avastin (regardless of insurance coverage) with a household adjusted gross income of up to $100,000. Patients must be receiving Avastin for an FDA-approved indication.

Single Point of Contact (SPOC)
Monday–Friday, 6 am–5 pm PST
Phone: 888.249.4918
Fax: 888.249.4919

Genentech BioOncology's SPOC provides timely, one-step reimbursement assistance. Oncology case managers will assist callers by: investigating benefits for new patients and those changing insurance or facing open enrollment, assisting with prior authorizations, helping with appeals and coverage denials, searching for alternative coverage for patients, answering questions related to product reimbursement, and consulting on coding/billing issues. Financial services include uninsured patient programs.

Now available: information about co-pay assistance through independent public charities.

Gilead Reimbursement Support & Assistance Program
Monday–Friday, 9 am–5 pm, EST
800.226.2056

The Gilead Reimbursement Support & Assistance Program is a service staffed by representatives trained to answer questions concerning coverage and reimbursement for Viread® (tenofovir) DaunoXome® (daunorubicin citrate liposome injection) and Vistide® (cidofovir injection). The program offers a range of reimbursement support services including: contacting insurance companies to determine a patient’s coverage; researching information about insurers’ coverage policies for these products; educating third-party payers; assisting with prior authorization procedures and other ways to expedite reimbursement; providing information on billing codes and claims filing processes; helping to resolve denied claims; and assistance with appeals. The program may provide Viread Daunoxome and/or Vistide to patients who: do not have health insurance or do not qualify for government assistance programs, and meet the program’s financial criteria. Patients or providers may contact the program at (800) 226-2056 for additional information.

GSK Reimbursement Resource Center
Monday–Friday, 9 am– 6 pm, ET
Phone: 800.745.2967 or 800.699.3806
Fax: 866.216.5292

The GSK Reimbursement Resource Center is available to assist patients and healthcare professionals with coverage, coding and, reimbursement issues for over 50 GlaxoSmithKline products, including the following oncology products:

ARRANON® (nelarabine) Injection, BEXXAR® (Tositumomab and Iodine I 131 Tositumomab), HYCAMTIN® (topotecan Hcl), LEUKERAN® (chlorambucil), MYLERAN® (busulfan), TABLOID® brand Thioguanine, TYKERB® (lapatinib) and ZOFRAN® (ondansetron HCl).

Available services:
Verification of benefits/payer research
Denied/underpaid claims assistance
Prior authorization assistance
Coding and billing assistance
Alternate funding searches

Commitment to Access
Patients who have been prescribed TYKERB and have no insurance coverage may be eligible to receive TYKERB free of charge if they live in one of the 50 states or the District of Columbia and their income is at or below 500 percent of the federal poverty level (For example, $68,450 for a household of two. Income eligibility is adjusted for household size). For patients enrolled in a Medicare Part D plan, eligibility also requires documentation of $600 in expenditures on prescription medicines in the current calendar year. Patients who are eligible for Medicare and who have incomes below 135 percent of the federal poverty level may not be eligible for GSK's patient assistance programs if they qualify for full assistance under Medicare.

More information regarding Commitment to Access is available at www.CommitmentToAccess.com and by calling 1-866-475-3678.

Guilford CaRe (SM) Program
Monday–Friday, 9 am–5 pm, EST
877.90.WAFER (1.877.909.2337)

Guilford Pharmaceuticals offers the Guilford CaRe (SM) Program, a comprehensive case management program free of charge to patients, caregivers, medical billing staff at physicians’ offices and hospitals, to health care providers, and others with questions about insurance coverage, coding, and reimbursement for the GLIADEL® Wafer and related procedures. The program takes a case management approach to solving third-party product reimbursement questions. Through the CaRe(SM) Program, Guilford provides the GLIADEL® Wafer Reimbursement Hotline and the PAL(SM) (Patient Assistance Link) Program, which provides free replacement product to institutions for patients that meet eligibility criteria. Trained reimbursement associates are available to provide assistance in several areas including: billing and coding, insurance verification, prior authorization support, insurer education, policy monitoring, and claims appeals.

Destination Access
Monday–Friday, 7:00 am–7:00 pm, CST
Phone: 800.861.0048
Fax: 888.761.2370

The service is designed to assist callers from the medical community with reimbursement issues surrounding Erbitux and all of ImClone System's products. The hotline is staffed by trained reimbursement specialists who will provide information on third-party coverage guidelines, claim requirements of individual third-party payers, limitations of specific policies, drug and procedures coding, and names and addresses of third-party payers. The hotline offers assistance in providing details on claim form submission, identifying reasons for claim rejection, providing guidelines and literature for claim appeals, facilitating prior authorization requests, and contacting insurers when appropriate in the process of claim submission. The hotline is designed for providers in the United States.

Ligand Reimbursement Support Program
Monday–Friday, 9 am–5 pm, EST
877.6LIGAND
877.654.4263
Professional Services
Monday–Friday, 9 am–7 pm EST
800.964.5836

The Ligand Reimbursement Support Program provides health care professionals with reimbursement assistance. The reimbursement specialists answer coding and billing questions; provide plan-specific product coverage information; and assist with the prior authorization and/or appeal processes.

The Patient Assistance Program (PAP) provides products free of charge to qualified, uninsured, indigent patients. Ligand Pharmaceuticals, Inc. reserves the right to modify or discontinue the program without notice.

Professional Services provides product information, including peer-reviewed clinical study publications, in response to requests from the medical professional community.

Targretin® gel 1% is indicated for the topical treatment of cutaneous lesions in patients with CTCL (Stage 1A 1B) who have refractory or persistent disease after other therapies, or who have not tolerated other therapies.

Targretin® capsule(s) is indicated for use in the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.

ONTAK® is indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the IL2 receptor.

Panretin® gel 0.1% is indicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.

Ethyol® Protect Program
Monday–Friday, 9 am–5 pm, ET
877.633.4411

The Ethyol Protect Program is a toll-free service that provides assistance to healthcare providers with coding and coverage verification, claims submissions, and appeals for Ethyol® (amifostine). As part of the reimbursement assistance services, reimbursement counselors will help physicians and patients assess their individual reimbursement situation by helping to verify their current insurance coverage, find out how individuals can access that coverage, and help to identify alternate insurance sources. For those patients who have followed the appropriate appeal procedures and are still denied coverage, assistance may be available to physicians in the form of product replacement. Additionally, product assistance in the form of free drug is available to financially needy individuals who meet the program's criteria. Pre-registration is required for both programs. Physicians, patients, and others needing reimbursement assistance for Ethyol should call 1-877-MEDI-411 (1-877-633-4411), one name, one source, one number, for Ethyol.

MGI Pharma Access Program (MAP)
1-877-MGI-MAPO
1-877-644-6270

This resource addresses: Aloxi, Dacogen, Hexalen, Gliadel Wafer

MGI product information
Indigent program
Reimbursement questions
Prior authorization
Referral to co-pay assistance programs
Insurance verification
Coding questions
Appeal assistance
Referral to disease-state assistance programs
Letter to Medical Necessity

VELCADE® Reimbursement Assistance Program
Monday–Friday, 9 am–7 pm, ET
866.VELCADE
866.835.2233

This program is a full-service hotline for healthcare providers, patients and caregivers. Reimbursement Specialists verify health insurance coverage and eligibility; obtain pre-authorization; assess each patient’s drug coverage; and clarify any co-payments obligations patients may have relative to VELCADE® (bortezomib) for Injection. In cases where patients have insufficient health insurance coverage, Reimbursement Specialists will help determine if alternative funding sources for VELCADE are available. If no other sources of drug coverage can be identified, patients will be evaluated for the Velcade Patient Assistance Program and, if eligible, will receive VELCADE free of charge.

The Reimbursement Hotline for Zometa®, Femara®, Gleevec™, and Exjade®
Zometa®: 866.4.ZOMETA®
Femara®: 866.4.FEMARA®
Gleevec™:877.GLEEVEC™
Exjade®: 1-888-90E-PASS
Monday to Friday, 9:00 am–8:00 pm EST

The Reimbursement Hotline hours of operation for Sandostatin LAR Depot® are:
Monday–Friday, 9:00 am–5:00 pm EST

The Sandostatin LAR Depot® Reimbursement Hotline:
877.LAR.HELP

The Zometa®, Femara®, Gleevec™, Exjade®, and Sandostatin LAR Depot® reimbursement program is available to assist health care providers with the following services:

Insurance Verification:
The program verifies patients’ medical benefits, helps determine insurance coverage for ZOMETA®, Femara®, Gleevec™, Exjade®, and Sandostatin LAR Depot® and clarifies any co-payment obligations they may have relative to ZOMETA®, Femara®, Gleevec™, Exjade®, and Sandostatin LAR Depot®.

Denial/Appeals:
The program assists providers to obtain appropriate reimbursement. Coding/Billing Questions: In addition, the program staff will assist providers with coding and billing questions.

Alternate Funding Searches:
The program staff will search for possible assistance for those patients with insufficient medical benefit coverage. Program staff will help determine if there are additional sources of funding that could help alleviate or reduce the cost of ZOMETA®, Femara®, Gleevec™, Exjade®, and Sandostatin LAR Depot® for the patient.

Patient Assistance Program:
The program screens indigent patients who do not have any benefit coverage for patient assistance eligibility. This process includes gathering income, assets, insurance, and residency information needed to determine eligibility. If eligible, these patients will qualify for free drug based on their residency status, insurance status, household size and household income.

Information Requests:
Mails product information materials to callers. Letter of Medical Necessity: The hotline provides copies of sample letters of medical necessity to doctors to support their claims.

Reimbursement Hotline for DOXIL®
(doxorubicin HCI liposome injection) Doxiline
Monday–Friday, 9 am–8 pm, EST
Phone: 800.609.1083
Fax: 800.987.5572

PROCRITline Reimbursement Hotline for PROCRIT® (Epoetin alfa)
for nondialysis use.
Monday–Friday, 9 am–8 pm, EST
800.553.3851 phone
800.987.5572 fax

LEUSTATIN® (cladribine) injection
Monday–Friday, 9 am–8 pm, EST
Phone: 800.553.3851
Fax: 800.987.5572

The program will ensure that PROCRIT, LEUSTATIN, and DOXIL are made available to any persons who meet specific medical criteria and lack financial resources and third-party coverage necessary to obtain treatment. A specialist will determine the patient’s eligibility. Patient eligibility application forms are available by accessing the 800 numbers or may be obtained online. This call can help determine if a patient is eligible to enroll in the program or is eligible for an alternative program if other sources of funding are identified.

Oncology Reimbursement Assistance Program: FirstRESOURCE
Monday–Friday, 9:00 am–8:00 pm, EST
Phone: 1.877.744.5675

Reimbursement assistance is available for all Pfizer oncology products, which include Aromasin® (exemestane tablets), Camptosar® (irinotecan HCI injection), Ellence® (epirubicin hydrochloride injection), Sutent (R) (sunitinib malate capsules) and additional oncology products.

For All FirstRESOURCE Services: Call 1-877-744-5675 (toll free) to reach a FirstRESOURCE counselor. If a counselor is not available, callers can leave a confidential message and calls will be returned within 1 business day. Assistance for non-English speaking individuals is available. FirstRESOURCE counselors will provide specific information on all services and program requirements.

ONCOLINE^TM Reimbursement Hotline
Monday–Friday, 8:30 am–5 pm, ET
800.443.6676, option 2

Oncoline reimbursement specialists will provide health care professionals information on insurance coverage, claim coding and submission procedures, payment policies, and qualification and enrollment of eligible patients in the Roche Patient Assistance Program.

sanofi-aventis
PACT+
Monday–Friday
9 am – 8 pm, ET
1.800.996.6626
www.pactplusonline.com

Patient Assistance and Reimbursement Services
The PACT+ program provides patient assistance, alternative resources and reimbursement support to oncology patients and providers. Reimbursement Counselors are available to answer questions about Eloxatin® (oxaliplatin injection), Taxotere® (docetaxel), Elitek® (rasburicase), Anzemet® (dolasetron mesylate) and Nilandron® (nilutamide).

sanofi-aventis Oncology has established this toll-free patient assistance hotline as a resource to health care professionals, patients, family members, and payers. All callers receive personalized assistance from reimbursement counselors, who are specially trained to address coding questions, coverage and benefit verification, claim submission, payment policies, and other reimbursement issues regarding sanofi-aventis oncology products.

PACT+Provider Portal
The PACT+ Provider Portal is a secure web site accessible only to healthcare providers and reimbursement personnel who participate in the PACT+ program on behalf of their practice's needy patients. This tool is the first of its kind in oncology and offers improved workflow processes related to reimbursement/patient assistance program information, such as the ability to: streamline and prioritize PAP caseload, complete enrollment applications online, receive alerts and reminders about specific patient cases, track PAP product shipments, and easily access all patient-related information, including patient history, alerts/reminders, insurance benefit summaries, shipments, attachments, and case history.

To register for the PACT+ Provider Portal, please visit www.pactplusonline.com or call PACT+ at 1.800.996.6626 and select Option 2.

Please Note: Access to the PACT+ Provider Portal is restricted to physicians, staff, and administrators who currently have permission to view patients' charts and their PHI. The portal is not accessible to sanofi-aventis employees or to patients enrolled in the PACT+ Program. There are no charges associated with registration or use of this portal.

Schering Plough's Commitment to CareSM
Monday–Friday, 9 am–5 pm, EST
800.521.7157

Reimbursement Service:
The hotline offers a reimbursement search and financial assistance program for Intron® A (interferon alfa 2b, recombinant) for injection, and Temodar® capsules. Reimbursement specialists assist patients and health care professionals to access more reimbursement options, provide educational materials, and enroll uninsured patients into drug assistance programs based on financial status. Additional services include coverage verification/preauthorizations, answers to billing and coding questions, and assistance with appeals for claim denials.

Drug Information Service:
Schering's Drug Information Service, a central, computerized service available free of charge to health professionals, provides medical information about interferons, flutamide, and temozolomide. This specialized service collects data from international and national sources, including published literature, symposia, meeting abstracts, scientific reviews, editorials, and protocols, and compiles that information into a customized report for health care professionals. The service provides access to literature searches, information on indicated uses for drugs, and information about new medical uses of biologic therapy.

Reimbursement Support for Matulane® (procarbazine hydrochloride)
Monday–Friday, 9:00 am–5:00 pm, EST
Phone: 800.490.3262
Fax: 703.997.4020
Email: sigmataureimbursement@unitedbiosource.com

The Sigma-Tau Reimbursement Hotline is a full-service hotline resource for patients and healthcare professionals interested in reimbursement and patient assistance for Matulane® (procarbazine hydrochloride). The Sigma-Tau Reimbursement Hotline is a free resource providing information on reimbursement policies, billing and coding, and claims appeals. The Reimbursement Hotline consultants can conduct insurance verifications upon request. The consultants have in-depth knowledge of Medicare including Medicare Part D, Medicaid, and Managed Care Payers. The consultants can provide information about Sigma-Tau’s Patient Assistance Program (PAP) administered through NORD, which provides Matulane® to medically needy patients who are underinsured or uninsured and meet specific program eligibility criteria.

The Reimbursement Hotline also assists patients by reviewing their insurance options and referring appropriate patients to alternative funding resources, such as state- or county-based funding when appropriate.

Reimbursement Hotline
Monday–Friday, 7:30 am–5:00 pm, CST
800.453.8438, Option 2

A reimbursement information line for Lupron Depot® is available to both health care professionals and patients. Designed to speed Medicare and Medicaid reimbursement, the hotline provides information on CPT codes, national and local carrier HCPCS codes, payment policies, proper filing of insurance claims, and assistance with reimbursement problems.

TheraSeed® Palladium 103 Implants/Brachytherapy
Reimbursement Hotline
Monday–Friday, 9 am–4 pm, ET
877.773.9363

Theragenics Corporation has established a reimbursement hotline for TheraSeed Palladium 103 implants, a prostate cancer therapy. The hotline is available for Theragenics' customers and payers.

Oncology Reimbursement Hotline
Monday–Friday, 9 am– 8 pm, ET
888.638.6342

A reimbursement information line for Neumega® and Mylotarg® provides information on: patient assistance program, insurance verification/benefits eligibility, coding and billing questions, appeal support, and state-by-state Medicare guidelines.

Reimbursement Assistance Program
Monday–Friday, 8 am–5 pm, PST
800.609.1108

The Codman Model 3000 Constant Flow Implantable Pump is indicated for arterial delivery of FUDR, intraspinal delivery of preservative-free morphine sulfate, and intraspinal delivery of baclofen. The Codman Reimbursement Assistance Program provides information on third-party coverage and payment to facilitate reimbursement and minimize payer issues.

Breast Biopsy Reimbursement Hotline
Monday–Friday, 8 am–4:30 pm, ET
800.USE.ENDO, Option 2

Ethicon Endo-Surgery, Inc., a Johnson & Johnson Company, has established a reimbursement hotline to assist their customers with inquiries concerning reimbursement for the Mammotome Breast Biopsy System, and the INDIGO Laser Optic Treatment System for benign prostatic hypertrophy.

Customer Support
Monday–Friday, 8:30 am–4:30 pm, MT
800.578.0555

Please contact McKinley Customer Support with any issues or inquiries pertaining to McKinley Medical, LLLP products, including WalkMed® ambulatory infusion pumps, the Outbound® disposable syringe infuser, and beeLINE(TM) disposable infusion systems.

Prior Authorization and Coding Assistance
Monday–Friday, 8 am–6 pm, CST
800.940.2327

Reimbursement assistance is provided, such as prior authorization assistance to physicians related to Medtronic neurological implantable therapies, CPT coding/billing assistance, and support with challenging claim denials. Service is available to health care professionals and patients.